Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Yunxin J. Jiao"'
Autor:
Moshe Sade-Feldman, Yunxin J. Jiao, Jonathan H. Chen, Michael S. Rooney, Michal Barzily-Rokni, Jean-Pierre Eliane, Stacey L. Bjorgaard, Marc R. Hammond, Hans Vitzthum, Shauna M. Blackmon, Dennie T. Frederick, Mehlika Hazar-Rethinam, Brandon A. Nadres, Emily E. Van Seventer, Sachet A. Shukla, Keren Yizhak, John P. Ray, Daniel Rosebrock, Dimitri Livitz, Viktor Adalsteinsson, Gad Getz, Lyn M. Duncan, Bo Li, Ryan B. Corcoran, Donald P. Lawrence, Anat Stemmer-Rachamimov, Genevieve M. Boland, Dan A. Landau, Keith T. Flaherty, Ryan J. Sullivan, Nir Hacohen
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-11 (2017)
Resistance to immune-checkpoint blockade often occurs in treated patients. Here, the authors demonstrate that B2M loss is a mechanism of primary and acquired resistance to therapies targeting CTLA4 or PD-1 in melanoma patients.
Externí odkaz:
https://doaj.org/article/4b7fd694a84645dbafce545e168de8d2
Autor:
Lyn M. Duncan, Oliver Spiro, Jian Carrot-Zhang, Monica Arniella, Michal Barzily-Rokni, Jonathan H. Chen, Gavin Ha, Dimitri Livitz, Anat Stemmer-Rachamimov, Genevieve M. Boland, Hans Vitzthum, Matthew Meyerson, Moshe Sade-Feldman, Chip Stewart, Donald P. Lawrence, Liudmila Elagina, Nir Hacohen, Keren Yizhak, Anna L.K. Gonye, Shauna M. Blackmon, Ignaty Leshchiner, Jennifer A. Wargo, Samuel S. Freeman, Ziao Lin, Dennie T. Frederick, Yunxin J. Jiao, Arvind Ravi, Daniel Rosebrock, Gad Getz, Jaegil Kim, François Aguet, Ryan J. Sullivan, Marc R. Hammond, Keith T. Flaherty
Publikováno v:
Cancer Research. 80:6670-6670
Cancer immunotherapy with checkpoint blockade has improved survival and outcomes in melanoma, but still a majority of patients do not respond. Both high tumor mutation burden (TMB) and high T cell infiltration have been associated with response, but
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::06e01e7d575e3664d347cc937b2a9609
https://doi.org/10.1158/1538-7445.am2020-6670
https://doi.org/10.1158/1538-7445.am2020-6670
Autor:
Lyn M. Duncan, Mehlika Hazar-Rethinam, Yunxin J. Jiao, Jonathan H. Chen, Genevieve M. Boland, Jean Pierre Eliane, Dimitri Livitz, Marc R. Hammond, Keith T. Flaherty, Gad Getz, Moshe Sade-Feldman, Viktor A. Adalsteinsson, Brandon Nadres, Michael S. Rooney, Donald P. Lawrence, Keren Yizhak, Ryan J. Sullivan, Bo Li, Shauna M. Blackmon, Michal Barzily-Rokni, Dennie T. Frederick, John P. Ray, Nir Hacohen, Ryan B. Corcoran, Daniel Rosebrock, Emily E. Van Seventer, Sachet A. Shukla, Anat Stemmer-Rachamimov, Dan A. Landau, Hans Vitzthum, Stacey L. Bjorgaard
Publikováno v:
Nature Communications
Nature Communications, Vol 8, Iss 1, Pp 1-11 (2017)
Nature Communications, Vol 8, Iss 1, Pp 1-11 (2017)
Treatment with immune checkpoint blockade (CPB) therapies often leads to prolonged responses in patients with metastatic melanoma, but the common mechanisms of primary and acquired resistance to these agents remain incompletely characterized and have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f367b41ce7c0bc32cce511c4473c2209
https://pubmed.ncbi.nlm.nih.gov/29070816
https://pubmed.ncbi.nlm.nih.gov/29070816